Interestingly, the activin-SMAD pathway, a downstream target of CDK4/6 (independent of Rb) was shown to be a good target for palbociclib in CREB3L1-deficient T47D luminal A breast cancer cells27. This evidence concerns the gene CDK4 and breast cancer.